Pharmaceutical industry observers are concerned about some of the drugs that were slashed from Express Scripts’ 2019 National Preferred Formulary.
The first medication approved by FDA as part of an expedited generic drug program is one that has been in short supply.
FDA okayed iobenguane I 131 (Azedra, Progenics Pharmaceuticals) injection for IV use to treat rare tumors of the adrenal gland.
FDA recently approved the first and only complete darunavir-based single-tablet regiment to treat HIV-1 in treatment-naïve and certain virologically suppressed adults.
A breast cancer drug is the first approval from FDA in 2 new pilot programs that make the development and review of cancer drugs more efficient.
Ivosidenib (Tibsovo, Agios Pharma) is the first drug approved for acute myeloid leukemia (AML) patients with a specific genetic mutation.
FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.
Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.
FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.
A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.